Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S Staddon is active.

Publication


Featured researches published by S Staddon.


Psychopharmacology | 2002

Clinical applications of pharmacogenetics in psychiatry.

S Staddon; Maria Arranz; D Mancama; Ignacio Mata; Robert Kerwin

Abstract. Pharmacogenetic research has identified response-related mutant variants in metabolic enzymes and drug-targeted receptors. Allelic variants of dopaminergic and serotonergic receptors have been associated with clinical outcome and adverse events such as movement disorders. Deficient metabolic enzymes have been related to drug accumulation and toxic events. This information will help to design safer and more efficient drugs. However, the field is moving rapidly towards a new goal: the application of pharmacogenetics as a clinical tool for the prediction of treatment outcome. The first studies in this direction have proved the feasibility of using genetic information for the prediction of response to antipsychotic drugs and to treatment of Alzheimers disease. New strategies investigating genes related to specific symptoms and side-effects have produced encouraging results that can contribute to the improvement of the levels and accuracy of the predictions. This review tries to summarise recent advances and provides an overview of future clinical applications.


Schizophrenia Research | 2005

Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population

S Staddon; Maria Arranz; D Mancama; F Perez-Nievas; Iñaki Arrizabalaga; Richard Anney; Paul Robert Buckland; Amanda Elkin; Sarah Osborne; Janet Munro; Ignacio Mata; Robert Kerwin

There are several lines of evidence implicating the dopamine D3 receptor in the pathophysiology of schizophrenia. The Ser9Gly polymorphism of the dopamine D3 receptor gene (DRD3) has been the most extensively investigated DRD3 variant in connection with the disease but results have been inconclusive. Recent reports indicate that the Ser9Gly polymorphism is in linkage disequilibrium with other markers, but association studies between DRD3 haplotypes and schizophrenia have had mixed results. Genetic heterogeneity may be one of the causes of contradicting results. In order to clarify the role of DRD3 alterations in the aetiology of disease, we have investigated three D3 genetic variants (Ser9Gly, -205-G/A, -7685-G/C) in a sample of patients with schizophrenia or schizoaffective disorder (N=118) and controls (N=162) recruited from a human isolate from Navarra (Northern Spain) of Basque origin. Although no association was found between the Ser9Gly or the -205-A/G polymorphisms and disease, an excess of allele -7685-C was observed in patients (p=0.002 after correction for multiple analyses). Haplotype analysis shows the three markers to be in strong linkage disequilibrium (p<0.0001) and strongly associated with disease (p<1x 10(-5)). These results may suggest that these polymorphisms exert a combined or synergistic effect on susceptibility to schizophrenia, or are in linkage with an unknown causative factor. However, further replication in independent samples is required.


American Journal of Psychiatry | 2006

Association of the Dysbindin Gene With Bipolar Affective Disorder

Gerome Breen; Diana Prata; Sarah Osborne; Janet Munro; Maggie Sinclair; Tao Li; S Staddon; D Dempster; Ricardo Sáinz; B Arroyo; Robert Kerwin; David St Clair; David A. Collier


Psychiatric Genetics | 2006

The high-activity Val allele of the catechol-O-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis.

Ignacio Mata; Maria Arranz; S Staddon; J.M. López-Ilundain; Rafael Tabarés-Seisdedos; Robin M. Murray


American Journal of Medical Genetics | 2004

Allelic variations in CYP450 enzymes and olanzapine response

S Staddon; Judie English; J.M. López-Ilundain; Ignacio Mata; Maria Arranz; Robert Kerwin


Schizophrenia Research | 2002

The D3 receptor and improvement in positive symptoms of schizophrenia

S Staddon; Maria Arranz; D Mancama; M Beperet; Janet Munro; Sarah Osborne; David A. Collier; Ignacio Mata; Robert Kerwin


American Journal of Medical Genetics | 2005

The dysbindin gene is associated with bipolar affective disorder

Diana Prata; Gerome Breen; Sarah Osborne; Janet Munro; Maggie Sinclair; S Staddon; D Dempster; Ricardo Sáinz; Robert Kerwin; D. St Clair; D. A. Collier


American Journal of Medical Genetics | 2005

Pharmacogenetic prediction of ziprasidone response in schizophrenic patients

Ignacio Mata; Maria Arranz; F Perez-Nievas; D Mancama; S Staddon; Robert Kerwin


European Neuropsychopharmacology | 2004

S.4.07 Applications of pharmacogenetics and pharmacogenomics in the improvement of psychiatric treatment

D Mancama; Maria Arranz; S Staddon; Michael J. Parsons; David R. Clark; S Osborne; Janet Munro; Robert Kerwin


European Neuropsychopharmacology | 2004

S.4.02 Dopamine 3 (D3) receptors genetic variants: influence in schizophrenia and antipsychotic response

David Clark; S Staddon; Ignacio Mata; D Mancama; Maria Arranz; Robert Kerwin

Collaboration


Dive into the S Staddon's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ignacio Mata

University of Cantabria

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

B Arroyo

King's College London

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge